The abstract is read at the publisher; the summary is JClub's.
Cre-mediated EGFRvIII overexpression with homozygous p19-ARF deletion in GFAP-expressing glial cells produces spontaneous classical glioblastoma lesions, with 95% of mice reaching endpoint symptoms by 6 months.
- Why it matters: Few in vivo transgenic models capture classical GBM development in an intact immune microenvironment, limiting mechanistic work and therapeutic testing.
- What they did: The authors bred a novel mouse model using GFAP-driven Cre to induce EGFRvIII and p19-ARF loss, then assessed lesions by histology and proliferation markers, profiled tumors by bulk and single-cell RNA sequencing, and tested tumorigenicity via intracranial xenografts in NOD-SCID mice.
- The result: Tumors cluster with classical GBM, show upregulation of JAK/STAT and P13K/AKT downstream markers with intratumoral heterogeneity, and dissociated tumors generate xenograft tumors by 3 weeks post-injection.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.